Onconic Therapeutics Achieves Breakthrough with Australian Patent for Nesuparip, a Dual-target Anticancer Drug

Onconic Therapeutics secures an Australian patent for Nesuparip, a dual-target anticancer drug, offering new hope for PARP inhibitor-resistant cancer patients. This breakthrough de...